Trial reportCell reports. Medicine2025
Tegileridine for moderate-to-severe acute pain following abdominal surgery: A randomized, double-blind, phase 3 clinical trial.
Trial report in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Evaluation of the efficacy and safety of tegileridine at different doses in patients with postoperative pain: a meta-analysis of randomized controlled trials.Frontiers in pain research (Lausanne, Switzerland) · 2026Pooled it
- Tegileridine versus Sufentanil Patient-Controlled Intravenous Analgesia for Gastrointestinal Recovery in Elderly Patients Undergoing Laparoscopic Colorectal Cancer Surgery: A Randomized Controlled Trial.Drug design, development and therapy · 2026Trial
- Effect of tegileridine pretreatment on fentanyl-induced cough during general anesthesia induction: a randomized controlled trial.Frontiers in medicine · 2026Trial
- Tegileridine versus Sufentanil for Patient-Controlled Intravenous Analgesia After Cesarean Delivery: A Randomized Double-Blind Trial.Drug design, development and therapy · 2026Trial
- A Comparison of Tegileridine Fumarate versus Sufentanil on the Quality of Postoperative Recovery After Laparoscopic Sleeve Gastrectomy: A Preliminary Randomized Controlled Trial.Drug design, development and therapy · 2026Trial
- Tegileridine, a Biased μ-Opioid Receptor Agonist, versus Oxycodone for Postoperative Analgesia and Postoperative Nausea and Vomiting After Total Laparoscopic Hysterectomy: A Randomized, Double-Blind, Single-Center, Controlled Trial.Drug design, development and therapy · 2026Trial
- In Response.Anesthesia and analgesia · 2026Article
- Article
- Interpreting Gastrointestinal Recovery After Tegileridine-Based PCIA in Elderly Colorectal Surgery Patients [Letter].Drug design, development and therapy · 2026Article
- Establishing the Median Effective Dose of Tegileridine for Immediate Postoperative Analgesia Following Laparoscopic Colorectal Cancer Surgery: A Sequential Dose-Finding Study.Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tegileridine is a biased μ-opioid receptor agonist that selectively activates the G protein pathway, designed to provide analgesia with fewer opioid-related adverse effects. In this phase 3 study, 526 patients with postoperative pain after abdominal surgery were randomized and received placebo, tegileridine at 0.75 mg, tegileridine at 1.0 mg, or morphine. For the primary outcome of effective analgesia, the mean (SD) summed pain intensity difference at rest over the first 24 h from time 0 (SPID
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.